BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on drug discovery, development, and commercialization. It specializes in creating oral small-molecule and injectable protein therapeutics for patients with rare diseases, particularly hereditary angioedema (HAE). The company aims to improve the lives of patients by addressing their specific needs and collaborating with advocacy organizations to ensure access to its treatments. Founded in 1986, BioCryst operates globally and is dedicated to advancing novel therapeutics for complex medical conditions.
